{"entity":{"type":"insider","cik":"0001282930","url":"/insider/0001282930","json_url":"/insider/0001282930.json","name":"GORDON CARL L","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":160,"n_filings":58,"first":"2004-06-04","last":"2026-08-12","span_basis":"filed_date"},"name_variants":[{"name":"GORDON CARL L","source":"filing","n_filings":58,"first_seen":"2004-06-04","last_seen":"2026-08-12"}],"transactions":[{"id":9211164,"accession":"0000947871-26-000785","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-26-000785","line_url":"/filing/0000947871-26-000785#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"BlossomHill Therapeutics, Inc.","issuer_ticker":"BLSM","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":2714279.0,"shares_owned_after_display":"2,714,279","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-10","filed_date":"2026-08-12","scope":"insider"},{"id":5975045,"accession":"0000947871-26-000734","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000947871-26-000734","line_url":"/filing/0000947871-26-000734#line-2","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Scribe Therapeutics, Inc.","issuer_ticker":"SCTX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":15000000.0,"total_display":"15,000,000.00","total_whole":"15,000,000","shares_owned_after":1348825.0,"shares_owned_after_display":"1,348,825","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-27","filed_date":"2026-07-29","scope":"insider"},{"id":4939444,"accession":"0000947871-25-000385","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-25-000385","line_url":"/filing/0000947871-25-000385#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Compass Therapeutics, Inc.","issuer_ticker":"CMPX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3571428.0,"shares_display":"3,571,428","price_per_share":1.59,"price_display":"1.59","price_state":"stated","total_value":5678570.52,"total_display":"5,678,570.52","total_whole":"5,678,571","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-09","filed_date":"2025-04-11","scope":"insider"},{"id":4414630,"accession":"0000947871-25-000200","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000947871-25-000200","line_url":"/filing/0000947871-25-000200","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"MBX Biosciences, Inc.","issuer_ticker":"MBX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":143170.0,"shares_display":"143,170","price_per_share":10.84,"price_display":"10.84","price_state":"stated","total_value":1551962.8,"total_display":"1,551,962.80","total_whole":"1,551,963","shares_owned_after":747887.0,"shares_owned_after_display":"747,887","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-18","filed_date":"2025-02-19","scope":"insider","n_lines":2},{"id":4414622,"accession":"0000947871-25-000200","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000947871-25-000200","line_url":"/filing/0000947871-25-000200","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"MBX Biosciences, Inc.","issuer_ticker":"MBX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":47502.0,"shares_display":"47,502","price_per_share":9.868906572354849,"price_display":"9.87","price_state":"stated","total_value":468792.8,"total_display":"468,792.80","total_whole":"468,793","shares_owned_after":3205930.0,"shares_owned_after_display":"3,205,930","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-14","filed_date":"2025-02-19","scope":"insider","n_lines":2},{"id":2461887,"accession":"0000950170-24-107524","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-107524","line_url":"/filing/0000950170-24-107524","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"MBX Biosciences, Inc.","issuer_ticker":"MBX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":750000.0,"shares_display":"750,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":12000000.0,"total_display":"12,000,000.00","total_whole":"12,000,000","shares_owned_after":3158428.0,"shares_owned_after_display":"3,158,428","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider","n_lines":2},{"id":2942920,"accession":"0000947871-24-000703","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000947871-24-000703","line_url":"/filing/0000947871-24-000703","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Keros Therapeutics, Inc.","issuer_ticker":"KROS","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250000.0,"shares_display":"250,000","price_per_share":44.01,"price_display":"44.01","price_state":"stated","total_value":11002500.0,"total_display":"11,002,500.00","total_whole":"11,002,500","shares_owned_after":899212.0,"shares_owned_after_display":"899,212","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-13","filed_date":"2024-08-15","scope":"insider","n_lines":2},{"id":2672499,"accession":"0000947871-24-000628","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000947871-24-000628","line_url":"/filing/0000947871-24-000628","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5188.0,"shares_display":"5,188","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":51880.0,"total_display":"51,880.00","total_whole":"51,880","shares_owned_after":4839412.0,"shares_owned_after_display":"4,839,412","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-16","filed_date":"2024-07-17","scope":"insider","n_lines":3},{"id":2672485,"accession":"0000947871-24-000628","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000947871-24-000628","line_url":"/filing/0000947871-24-000628","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50976.0,"shares_display":"50,976","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":509760.0,"total_display":"509,760.00","total_whole":"509,760","shares_owned_after":4843421.0,"shares_owned_after_display":"4,843,421","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-15","filed_date":"2024-07-17","scope":"insider","n_lines":3},{"id":2107828,"accession":"0000947871-24-000498","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-24-000498","line_url":"/filing/0000947871-24-000498#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"BiomX Inc.","issuer_ticker":"PHGE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":null,"owner_name":"OrbiMed Israel GP Ltd.; GORDON CARL L; OrbiMed Israel BioFund GP Limited Partnership; Chimovits Erez","owner_display_name":"OrbiMed Israel GP Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24344.0,"shares_display":"24,344","price_per_share":0.3812,"price_display":"0.38","price_state":"stated","total_value":9279.9328,"total_display":"9,279.93","total_whole":"9,280","shares_owned_after":13773653.0,"shares_owned_after_display":"13,773,653","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-05-15","filed_date":"2024-05-20","scope":"insider"},{"id":2753365,"accession":"0001104659-24-008797","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-24-008797","line_url":"/filing/0001104659-24-008797","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"ArriVent Biopharma, Inc.","issuer_ticker":"AVBP","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":444444.0,"shares_display":"444,444","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":7999992.0,"total_display":"7,999,992.00","total_whole":"7,999,992","shares_owned_after":1513664.0,"shares_owned_after_display":"1,513,664","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-01-31","scope":"insider","n_lines":2},{"id":2414730,"accession":"0000950170-24-008052","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-008052","line_url":"/filing/0000950170-24-008052","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Adicet Bio, Inc.","issuer_ticker":"ACET","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3125000.0,"shares_display":"3,125,000","price_per_share":2.4,"price_display":"2.40","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":7526359.0,"shares_owned_after_display":"7,526,359","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-25","filed_date":"2024-01-26","scope":"insider","n_lines":3},{"id":8399447,"accession":"0000947871-23-000761","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000947871-23-000761","line_url":"/filing/0000947871-23-000761","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Theseus Pharmaceuticals, Inc.","issuer_ticker":"THRX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":479932.0,"shares_display":"479,932","price_per_share":3.05,"price_display":"3.05","price_state":"stated","total_value":1463792.6,"total_display":"1,463,792.60","total_whole":"1,463,793","shares_owned_after":17063000.0,"shares_owned_after_display":"17,063,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-17","filed_date":"2023-07-19","scope":"insider","n_lines":2},{"id":8749449,"accession":"0000947871-23-000714","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000947871-23-000714","line_url":"/filing/0000947871-23-000714","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Adicet Bio, Inc.","issuer_ticker":"ACET","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":875000.0,"shares_display":"875,000","price_per_share":2.09,"price_display":"2.09","price_state":"stated","total_value":1828750.0,"total_display":"1,828,750.00","total_whole":"1,828,750","shares_owned_after":5685259.0,"shares_owned_after_display":"5,685,259","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-27","filed_date":"2023-06-29","scope":"insider","n_lines":4},{"id":8137060,"accession":"0000947871-23-000540","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000947871-23-000540","line_url":"/filing/0000947871-23-000540","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":981023.0,"shares_display":"981,023","price_per_share":2.82,"price_display":"2.82","price_state":"stated","total_value":2766484.86,"total_display":"2,766,484.86","total_whole":"2,766,485","shares_owned_after":1368339.0,"shares_owned_after_display":"1,368,339","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-05","filed_date":"2023-05-08","scope":"insider","n_lines":2},{"id":8137052,"accession":"0000947871-23-000540","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000947871-23-000540","line_url":"/filing/0000947871-23-000540","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":479909.0,"shares_display":"479,909","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":1319749.75,"total_display":"1,319,749.75","total_whole":"1,319,750","shares_owned_after":4738453.0,"shares_owned_after_display":"4,738,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-04","filed_date":"2023-05-08","scope":"insider","n_lines":3},{"id":8064367,"accession":"0000947871-23-000516","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000947871-23-000516","line_url":"/filing/0000947871-23-000516","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":338262.0,"shares_display":"338,262","price_per_share":2.67,"price_display":"2.67","price_state":"stated","total_value":903159.54,"total_display":"903,159.54","total_whole":"903,160","shares_owned_after":4425462.0,"shares_owned_after_display":"4,425,462","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-02","filed_date":"2023-05-02","scope":"insider","n_lines":3},{"id":8064354,"accession":"0000947871-23-000516","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000947871-23-000516","line_url":"/filing/0000947871-23-000516","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":716157.0,"shares_display":"716,157","price_per_share":2.62,"price_display":"2.62","price_state":"stated","total_value":1876331.34,"total_display":"1,876,331.34","total_whole":"1,876,331","shares_owned_after":4204852.0,"shares_owned_after_display":"4,204,852","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-01","filed_date":"2023-05-02","scope":"insider","n_lines":3},{"id":8064342,"accession":"0000947871-23-000516","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000947871-23-000516","line_url":"/filing/0000947871-23-000516","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Kinnate Biopharma Inc.","issuer_ticker":"KNTE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":350749.0,"shares_display":"350,749","price_per_share":2.55,"price_display":"2.55","price_state":"stated","total_value":894409.95,"total_display":"894,409.95","total_whole":"894,410","shares_owned_after":3737784.0,"shares_owned_after_display":"3,737,784","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-28","filed_date":"2023-05-02","scope":"insider","n_lines":3},{"id":8310413,"accession":"0000947871-23-000336","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-23-000336","line_url":"/filing/0000947871-23-000336#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"BiomX Inc.","issuer_ticker":"PHGE","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":null,"owner_name":"OrbiMed Israel GP Ltd.; OrbiMed Israel BioFund GP Limited Partnership; Chimovits Erez; GORDON CARL L","owner_display_name":"OrbiMed Israel GP Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":348000.0,"shares_display":"348,000","price_per_share":0.245,"price_display":"0.24","price_state":"stated","total_value":85260.0,"total_display":"85,260.00","total_whole":"85,260","shares_owned_after":3161489.0,"shares_owned_after_display":"3,161,489","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-03-17","scope":"insider"},{"id":6099069,"accession":"0000947871-22-001259","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-22-001259","line_url":"/filing/0000947871-22-001259#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":137931.0,"shares_display":"137,931","price_per_share":7.25,"price_display":"7.25","price_state":"stated","total_value":999999.75,"total_display":"999,999.75","total_whole":"1,000,000","shares_owned_after":4882854.0,"shares_owned_after_display":"4,882,854","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-23","filed_date":"2022-12-28","scope":"insider"},{"id":6452124,"accession":"0000947871-22-001163","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-22-001163","line_url":"/filing/0000947871-22-001163#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Compass Therapeutics, Inc.","issuer_ticker":"CMPX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":402000.0,"shares_display":"402,000","price_per_share":3.21,"price_display":"3.21","price_state":"stated","total_value":1290420.0,"total_display":"1,290,420.00","total_whole":"1,290,420","shares_owned_after":15219994.0,"shares_owned_after_display":"15,219,994","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-08","filed_date":"2022-11-10","scope":"insider"},{"id":6534519,"accession":"0000947871-22-001158","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000947871-22-001158","line_url":"/filing/0000947871-22-001158#line-1","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Theseus Pharmaceuticals, Inc.","issuer_ticker":"THRX","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":192000.0,"shares_display":"192,000","price_per_share":5.21,"price_display":"5.21","price_state":"stated","total_value":1000320.0,"total_display":"1,000,320.00","total_whole":"1,000,320","shares_owned_after":16734518.0,"shares_owned_after_display":"16,734,518","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-07","filed_date":"2022-11-09","scope":"insider"},{"id":6348932,"accession":"0000947871-22-000910","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000947871-22-000910","line_url":"/filing/0000947871-22-000910","is_derivative":false,"issuer_cik":"0001282930","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001282930","owner_cik":"0001282930","owner_name":"GORDON CARL L","owner_display_name":"GORDON CARL L","owner_url":"/insider/0001282930","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3690000.0,"shares_display":"3,690,000","price_per_share":2.42,"price_display":"2.42","price_state":"stated","total_value":8929800.0,"total_display":"8,929,800.00","total_whole":"8,929,800","shares_owned_after":4744923.0,"shares_owned_after_display":"4,744,923","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-16","filed_date":"2022-08-18","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":"2022-08-16|6348926","ledger_fault":false,"count":{"value":158,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":84,"open_market":true},{"code":"S","label":"Open-market sale","n":74,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":158},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001839970","name":"BlossomHill Therapeutics, Inc.","url":"/issuer/0001839970","role":"Director","n_filings":1,"first_seen":"2026-08-12","last_seen":"2026-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001853921","name":"Scribe Therapeutics, Inc.","url":"/issuer/0001853921","role":"Director","n_filings":1,"first_seen":"2026-07-29","last_seen":"2026-07-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001738021","name":"Compass Therapeutics, Inc.","url":"/issuer/0001738021","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2020-06-23","last_seen":"2025-04-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001776111","name":"MBX Biosciences, Inc.","url":"/issuer/0001776111","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2024-09-17","last_seen":"2025-02-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001664710","name":"Keros Therapeutics, Inc.","url":"/issuer/0001664710","role":"Director","n_filings":2,"first_seen":"2020-04-13","last_seen":"2024-08-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001831363","name":"Terns Pharmaceuticals, Inc.","url":"/issuer/0001831363","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2021-02-09","last_seen":"2024-07-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001739174","name":"BiomX Inc.","url":"/issuer/0001739174","role":"Ten percent owner","n_filings":2,"first_seen":"2023-03-17","last_seen":"2024-05-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001868279","name":"ArriVent Biopharma, Inc.","url":"/issuer/0001868279","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2024-01-31","last_seen":"2024-01-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001720580","name":"Adicet Bio, Inc.","url":"/issuer/0001720580","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2023-06-29","last_seen":"2024-01-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001745020","name":"Theseus Pharmaceuticals, Inc.","url":"/issuer/0001745020","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2021-10-14","last_seen":"2023-07-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001797768","name":"Kinnate Biopharma Inc.","url":"/issuer/0001797768","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2020-12-04","last_seen":"2023-05-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001796280","name":"Oric Pharmaceuticals, Inc.","url":"/issuer/0001796280","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2020-04-28","last_seen":"2021-03-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001714798","name":"Prevail Therapeutics Inc.","url":"/issuer/0001714798","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2019-06-26","last_seen":"2019-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001595893","name":"Turning Point Therapeutics, Inc.","url":"/issuer/0001595893","role":"Director","n_filings":1,"first_seen":"2019-04-24","last_seen":"2019-04-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001653087","name":"Alector, Inc.","url":"/issuer/0001653087","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2019-02-11","last_seen":"2019-02-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001501697","name":"Arsanis, Inc.","url":"/issuer/0001501697","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2017-11-20","last_seen":"2017-11-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001453687","name":"SELECTA BIOSCIENCES INC","url":"/issuer/0001453687","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2016-06-29","last_seen":"2016-06-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Director","n_filings":1,"first_seen":"2016-05-11","last_seen":"2016-05-11"},{"type":"issuer","type_label":"ISSUER","cik":"0000897448","name":"AMARIN CORP PLC\\UK","url":"/issuer/0000897448","role":"Director","n_filings":12,"first_seen":"2011-03-02","last_seen":"2012-09-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001396814","name":"Pacira Pharmaceuticals, Inc.","url":"/issuer/0001396814","role":"Director","n_filings":1,"first_seen":"2011-02-10","last_seen":"2011-02-10"},{"type":"issuer","type_label":"ISSUER","cik":"0000882796","name":"BIOCRYST PHARMACEUTICALS INC","url":"/issuer/0000882796","role":"Director","n_filings":1,"first_seen":"2005-12-06","last_seen":"2005-12-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001070494","name":"ACADIA PHARMACEUTICALS INC","url":"/issuer/0001070494","role":"Director","n_filings":2,"first_seen":"2004-06-04","last_seen":"2005-04-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001282930","retrieved_at":"2026-08-27T07:42:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}